Eli Lilly and Company $LLY Shares Acquired by DeDora Capital Inc.

DeDora Capital Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,991 shares of the company’s stock after acquiring an additional 233 shares during the period. DeDora Capital Inc.’s holdings in Eli Lilly and Company were worth $2,332,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Precedent Wealth Partners LLC grew its stake in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after buying an additional 39 shares during the last quarter. Capital Advisors Inc. OK grew its stake in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares during the last quarter. Family CFO Inc purchased a new position in Eli Lilly and Company during the 2nd quarter worth approximately $54,000. Duquesne Family Office LLC grew its stake in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. Finally, Corient IA LLC purchased a new position in Eli Lilly and Company during the 1st quarter worth approximately $570,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Finally, Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $939.12.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Down 1.9%

Eli Lilly and Company stock opened at $803.53 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The company has a market cap of $760.51 billion, a PE ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. The stock’s 50 day moving average price is $753.09 and its 200 day moving average price is $765.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the business earned $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.